Accelerating The Industrialization Of CGT Manufacturing

Inhalable therapies offer a fast-acting and efficient method for drug delivery, and their demand is growing with the increasing incidence of respiratory diseases. The expiration of the patent for GSK’s Diskus DPI, which was a high-speed powder filling system, will enable lower-cost medications and improved access to an increased number of therapeutic options.

This presents an opportunity for a new product, cryoFIL, that can handle more challenging, highly potent, and dusty powders with increased containment. This next-generation platform is designed to fill DPIs up to five times faster than other options on the market, while also increasing containment and the ability to process challenging powders. As a result, it creates new opportunities to develop novel DPI formulations with greater flexibility.